Explore

Trendline Trendline
Precision BioSciences to Announce Q1 2026 Financial Results Amid Gene Editing Advancements

Precision BioSciences to Announce Q1 2026 Financial Results Amid Gene Editing Advancements

Precision BioSciences to Announce Q1 2026 Financial Results Amid Gene Editing Advancements
Trendline Trendline
Lucid Diagnostics Announces Upcoming Business Update Conference Call

Lucid Diagnostics Announces Upcoming Business Update Conference Call

Lucid Diagnostics Announces Upcoming Business Update Conference Call
Trendline Trendline
DiaMedica Therapeutics to Announce Q1 2026 Financial Results and Business Update

DiaMedica Therapeutics to Announce Q1 2026 Financial Results and Business Update

DiaMedica Therapeutics to Announce Q1 2026 Financial Results and Business Update
Trendline Trendline
Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases
Trendline Trendline
Co-Diagnostics to Release Q1 2026 Financial Results, Hosts Webcast for Analysts

Co-Diagnostics to Release Q1 2026 Financial Results, Hosts Webcast for Analysts

Co-Diagnostics to Release Q1 2026 Financial Results, Hosts Webcast for Analysts
Trendline Trendline
Lucid Diagnostics Announces Upcoming Business Update Conference Call for Q1 2026

Lucid Diagnostics Announces Upcoming Business Update Conference Call for Q1 2026

Lucid Diagnostics Announces Upcoming Business Update Conference Call for Q1 2026
Trendline Trendline
Co-Diagnostics to Release Q1 2026 Financial Results and Host Webcast

Co-Diagnostics to Release Q1 2026 Financial Results and Host Webcast

Co-Diagnostics to Release Q1 2026 Financial Results and Host Webcast
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis

Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis

Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis
Trendline Trendline
Travere Therapeutics to Announce Q1 2026 Financial Results, Impacting Rare Disease Community

Travere Therapeutics to Announce Q1 2026 Financial Results, Impacting Rare Disease Community

Travere Therapeutics to Announce Q1 2026 Financial Results, Impacting Rare Disease Community
Trendline Trendline
Lilly and Profluent Bio Forge $2.25 Billion Deal to Advance Genetic Medicine

Lilly and Profluent Bio Forge $2.25 Billion Deal to Advance Genetic Medicine

Lilly and Profluent Bio Forge $2.25 Billion Deal to Advance Genetic Medicine
Trendline Trendline
CareDx Reports 39% Revenue Growth in Q1 2026, Raises Annual Guidance

CareDx Reports 39% Revenue Growth in Q1 2026, Raises Annual Guidance

CareDx Reports 39% Revenue Growth in Q1 2026, Raises Annual Guidance
Trendline Trendline
Zimmer Biomet Reports Strong Q1 2026 Financial Results with Increased Earnings

Zimmer Biomet Reports Strong Q1 2026 Financial Results with Increased Earnings

Zimmer Biomet Reports Strong Q1 2026 Financial Results with Increased Earnings